Company: ENTXW
Filing Date: 2025-05-14
Form Type: PRE 14A
Source: 0001178913-25-001794
Chunk: 57

Company: Entera Bio Ltd.
Filing Date: 2025-05-14
Form: PRE 14A
Chunk 57
---
 reflected as reported in our audited consolidated financial statements for the applicable fiscal year. |

Pay versus Performance Comparative Disclosure In accordance with SEC rules, the Company is providing the following narrative disclosure regarding the relationships between information presented in the pay versus performance tables above. Compensation Actually Paid and Cumulative Total Shareholder Return During 2023 and 2024, compensation actually paid (“CAP”) to our PEO increased from $483 thousand in fiscal year 2023 to $2,187 thousands in fiscal year 2024. Average compensation actually paid to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, the value of an investment of $100 in our Ordinary Shares on the last trading day of 2022 decreased by $18 to $82 during fiscal 2023 and increased by $230 to $312 during fiscal 2024. 33 The following graph sets forth the relationship between CAP to our PEO, the average of CAP to our Non-PEO NEOs, and our cumulative TSR over the three most recently completed fiscal years. Compensation Actually Paid and Net Loss During 2023 and 2024, CAP to our PEO increase from $483 thousand in fiscal year 2023 to $2,187 thousand in fiscal year 2024. Average CAP to our Non-PEO NEOs increased from $314 in fiscal year 2023 to $849 thousand in fiscal year 2024. Over the same period, our net loss increased by $652 thousand during fiscal year 2024 (from a net loss in fiscal year 2023 of $8,889 thousand to a net loss in fiscal year 2024 of $9,541 thousand).

34

| PROPOSAL ONE — ELECTION OF DIRECTORS |

Director Nominees In accordance with the Israeli Companies Law and without derogating from the appointment requirements listed above, each of the nominees has certified to us that he meets all the requirements of the Israeli Companies Law for election as a director of a public company, possesses the necessary qualifications and has sufficient time in order to fulfill his duties as our director, taking into account our size and special needs. Shareholders are being asked to elect the director nominees listed below.

| Name        
 Haya Taitel | Term Expires                        
 2028 Annual Meeting of shareholders |

Unless otherwise instructed, the proxy holders will vote the proxies received by them for the director nominees listed above. In the event that any nominee is unable